Abstracts tagged "systemic lupus erythematosus (SLE) and treatment"

Abstract Number: 2259 • 2012 ACR/ARHP Annual Meeting
Limitations of Current Treatment for Systemic Lupus Erythematosus: A Patient and Physician Survey
V. Strand¹, C. Galateanu², S. Lobosco³, D.S. Pushparajah², J. Sayers⁴ and R.F. van Vollenhoven⁵, ¹Stanford University, Portola Valley, CA, ²UCB Pharma, Brussels, Belgium, ³Adelphi Real World Ltd., Macclesfield, United Kingdom, ⁴Adelph Real World Ltd., Macclesfield, United Kingdom, ⁵Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Current SLE treatment regimens follow an ‘add-on' paradigm: typically, therapies are added as the activity of a patient's disease increases. Most current treatments, particularly…
Abstract Number: 1448 • 2012 ACR/ARHP Annual Meeting
Inhibition of Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses the Autoimmunity in Lupus-Prone Mice
Kunihiro Ichinose¹, Atsushi Kawakami² and George C. Tsokos³, ¹Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA
Inhibition of Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses the Autoimmunity in Lupus-Prone Mice. Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease associated with abnormal…
Abstract Number: 1420 • 2012 ACR/ARHP Annual Meeting
Ethnicity and B Cell Depletion Therapy in Systemic Lupus Erythematosus
A. Lois-Iglesias¹, J. Ishorari² and D.A. Isenberg², ¹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain. University College London, London, United Kingdom, ²Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose:The aim of this study was to determine if there is any relation between ethnicity and outcome in patients with SLE treated with B cell…
Abstract Number: 1421 • 2012 ACR/ARHP Annual Meeting
Antimalarials Protect Systemic Lupus Erythematosus Patients From Damage Accrual During the First Five Years of the Disease
Ioana Ruiz-Arruza¹, D. D. Gladman¹, Dominique Ibanez² and Murray B. Urowitz², ¹Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Studies in the last 20 years have demonstrated that antimalarials (AM) prevent flares, protect from damage accrual, reduce the risk of thrombosis and increase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.